alexa Indoleamine 2,3-Dioxygenase as A Prognostic Factor in P
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Indoleamine 2,3-Dioxygenase as A Prognostic Factor in Patients with Non-Small Cell Lung Cancer

Takeshi Hanagiri1*, Misako Fukumoto2, Yukiko Koyanagi2, Yukari Furutani2 and Fumihiro Tanaka2
1Department of Chest Surgery, Iizuka Hospital, Iizuka, Fukuoka, Japan
2Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Corresponding Author : Takeshi Hanagiri
Department of Chest Surgery, Iizuka Hospital
3-83 Yoshio, Iizuka, Fukuoka 820-8505, Japan
Tel: +81-0948-22-3800
Fax: +81-0948-29-5744
E-mail: [email protected]
Received July 07, 2014; Accepted September 24, 2014; Published October 01, 2014
Citation: Hanagiri T, Fukumoto M, Koyanagi Y, Furutani Y, Tanaka F (2014) Indoleamine2,3-Dioxygenase as A Prognostic Factor in Patients with Non-Small Cell Lung Cancer. J Clin Cell Immunol 5:260. doi: 10.4172/2155-9899.1000260
Copyright: © 2014 Hanagiri T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google
 

Abstract

Background: Indoleamine 2,3-dioxygenase (IDO) is an immunomodulatory enzyme produced by tumor cells and some alternatively activated macrophages and other immunoregulatory cells. The purpose of the present study was to evaluate the prognostic value of the relative expression of the forkhead/winged helix transcription factor 3 (Foxp3) and IDO in non-small cell lung cancer (NSCLC) tissues.

Methods: The NSCLC tissues from 141 patients who underwent complete surgical resection were collected at the time of surgery. The relative expression levels of Foxp3 and IDO in the tissues were determined by quantitative RT–PCR.

Results: The histological types of cancer seen in these patients included 105 adenocarcinomas, 24 squamous cell carcinomas and 12 other types of carcinoma. The average expression levels of Foxp3 and IDO relative to that of ß-actin in the NSCLC tissue were 0.052 ± 0.147% and 0.088 ± 0.157%, respectively. The relative expression of Foxp3 tended to increase with the relative expression of IDO (R=0.451, P=0.001). The five-year survival rates of the patients according to the relative expression of Foxp3 were 78.3% and 71.9% in the lower and higher groups, respectively. According to the relative expression of IDO, the five-year survival rate was 83.2% in the lower expression group, and 67.9% in the higher expression group. There was a significant difference between the lower and higher IDO expression groups (p=0.0389).

Conclusions: The expression of IDO tended to have a positive correlation with the expression of Foxp3. The higher expression of IDO was therefore a significantly unfavorable prognostic factor in patients with NSCLC.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords